William M. Pardridge

Founder at ArmaGen, Inc.

Consumer Services

Health Services

Profile

William M.
Pardridge is the founder of ArmaGen, Inc. where he holds the title of Director & Chief Scientific Officer since 2003.
He is currently a Professor-Emeritus at the University of California.
Dr. Pardridge received his undergraduate degree from the University of California, Los Angeles in 1969 and his doctorate degree from The Pennsylvania State University in 1974.

William M. Pardridge active positions

Companies	Position	Start
ArmaGen, Inc. ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.	Founder	01/01/2003
University of California	Corporate Officer/Principal	-

All active positions of William M. Pardridge

Training of William M. Pardridge

The Pennsylvania State University	Doctorate Degree
University of California, Los Angeles	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of William M. Pardridge's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
ArmaGen, Inc. ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.	Health Services